Research

The Center for Cancer Genome Discovery has merged with the Center for Precision Cancer Medicine. We are now the Center for Cancer Genomics.

Learn more.

Don’t Miss Our CCG Symposium: Genomic Approaches Toward Precision Cancer Medicine

March 13, 2020, Dana-Farber Jimmy Fund Auditorium

Keynote speakers: Kathleen Burns, MD, PhD, Chair, Department of Oncologic Pathology, Dana-Farber Cancer Institute; and Phillip Febbo, MD, Senior VP/Chief Medical Officer, Illumina

Announcement
Agenda
Registration

The Center for Cancer Genome Discovery (CCGD) is the research and development group within the Precision Cancer Medicine effort at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital. As part of that effort, CCGD continually evaluates and develops new sequencing assays and technologies, for both research and clinical use, which allows us to assist investigators pursuing novel questions and new techniques.

The three main components of our mission are:

• Technology development: To develop new technologies for the analysis of cancer genomes
• Collaborative research: To provide access to these genomic technologies to basic, translational, and clinical investigators at Dana-Farber and beyond
• Translation: To translate technologies to the clinical setting

Services

The Center for Cancer Genome Discovery can provide collaborators with comprehensive services that include personal consultation on the type of sequencing most suitable for project needs, preparation of sequencing libraries, and custom bait set design for targeted sequencing. Additionally, sequencing libraries prepared by CCGD are provided assistance with bioinformatic analysis. Sample types accepted include collaborator-prepared libraries or purified nucleic acid, including difficult samples such as cfDNA and FFPE nucleic acid.